INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
Therapy for ankylosing spondylitis (AS) is a challenge for a physician, primarily because of a small number of therapeutic alternatives. Interleukin-17 (IL17), a novel promising therapeutic target, has been recently disclosed. The first representative of the new group of drugs – anti-IL17A monoclon...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2016-09-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2255 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|